These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31630416)

  • 1. Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody.
    Sellberg F; Berglund D; Binder C; Hope J; Fontenot J; Griesemer A; Sykes M; Sachs DH; Berglund E
    Scand J Immunol; 2020 Jan; 91(1):e12839. PubMed ID: 31630416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients.
    Pruett TL; McGory RW; Wright FH; Pescovitz MD; Yang H; McClain JB
    Transplant Proc; 2009 Nov; 41(9):3655-61. PubMed ID: 19917362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.
    Bissonnette R; Langley RG; Papp K; Matheson R; Toth D; Hultquist M; Geba GP; White B
    Arch Dermatol Res; 2009 Jul; 301(6):429-42. PubMed ID: 19471949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity.
    Binder C; Sellberg F; Cvetkovski F; Berg S; Berglund E; Berglund D
    Front Immunol; 2021; 12():599526. PubMed ID: 33643309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.
    Langley RG; Papp K; Bissonnette R; Toth D; Matheson R; Hultquist M; White B
    Int J Dermatol; 2010 Jul; 49(7):818-28. PubMed ID: 20618506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322.
    Nizet Y; Chentoufi AA; de la Parra B; Lewalle P; Rouas R; Cornet A; Besse T; Mourad M; Malaise J; Squifflet JP; Bazin H; Latinne D
    Transplantation; 2000 Apr; 69(7):1420-8. PubMed ID: 10798765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody.
    Dehoux JP; Talpe S; Dewolf N; Otsuka M; Oike F; Jamar F; de la Parra B; Latinne D; Bazin H; Gianello P
    Transplantation; 2000 Jun; 69(12):2622-33. PubMed ID: 10910286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for CD2 antibodies (BTI-322 and its humanized form) in the in vivo elimination of human T lymphocytes infiltrating an allogeneic human skin graft in SCID mice: an Fcgamma receptor-related mechanism involving co-injected human NK cells.
    Snanoudj R; Rouleau M; Bidère N; Carmona S; Baron C; Latinne D; Bazin H; Charpentier B; Senik A
    Transplantation; 2004 Jul; 78(1):50-8. PubMed ID: 15257038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacodynamics of anti-CD2 monoclonal antibody treatment in cynomolgus macaques - an experimental study.
    Berglund E; Alonso-Guallart P; Danton M; Sellberg F; Binder C; Fröbom R; Berglund D; Llore N; Sakai H; Iuga A; Ekanayake-Alper D; Reimann KA; Sachs DH; Sykes M; Griesemer A
    Transpl Int; 2020 Jan; 33(1):98-107. PubMed ID: 31523849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin
    Binder C; Sellberg F; Cvetkovski F; Berglund E; Berglund D
    Front Immunol; 2020; 11():592553. PubMed ID: 33262770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
    O'Mahony D; Morris JC; Stetler-Stevenson M; Matthews H; Brown MR; Fleisher T; Pittaluga S; Raffeld M; Albert PS; Reitsma D; Kaucic K; Hammershaimb L; Waldmann TA; Janik JE
    Clin Cancer Res; 2009 Apr; 15(7):2514-22. PubMed ID: 19293260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.
    Przepiorka D; Phillips GL; Ratanatharathorn V; Cottler-Fox M; Sehn LH; Antin JH; LeBherz D; Awwad M; Hope J; McClain JB
    Blood; 1998 Dec; 92(11):4066-71. PubMed ID: 9834211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease.
    Adkins D; Ratanatharathorn V; Yang H; White B
    Transplantation; 2009 Jul; 88(2):198-202. PubMed ID: 19623014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro.
    Podestà MA; Binder C; Sellberg F; DeWolf S; Shonts B; Ho SH; Obradovic A; Waffarn E; Danzl N; Berglund D; Sykes M
    Am J Transplant; 2020 Jan; 20(1):88-100. PubMed ID: 31319439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells.
    Branco L; Barren P; Mao SY; Pfarr D; Kaplan R; Postema C; Langermann S; Koenig S; Johnson S
    Transplantation; 1999 Nov; 68(10):1588-96. PubMed ID: 10589960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion.
    Xu Y; Kolber-Simonds D; Hope JA; Bazin H; Latinne D; Monroy R; White-Scharf ME; Schuurman HJ
    Clin Exp Immunol; 2004 Dec; 138(3):476-83. PubMed ID: 15544625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies against human T cell adhesion molecules--modulation of immune function in nonhuman primates.
    Berlin PJ; Bacher JD; Sharrow SO; Gonzalez C; Gress RE
    Transplantation; 1992 Apr; 53(4):840-9. PubMed ID: 1348883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.
    Norman DJ; Vincenti F; de Mattos AM; Barry JM; Levitt DJ; Wedel NI; Maia M; Light SE
    Transplantation; 2000 Dec; 70(12):1707-12. PubMed ID: 11152101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.
    Brochstein JA; Grupp S; Yang H; Pillemer SR; Geba GP
    Pediatr Transplant; 2010 Mar; 14(2):233-41. PubMed ID: 19671093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis of human naive NK cells mediated by a rat IgG2b anti CD2 mAb through a fractricidal ADCC reaction.
    Nizet Y; Chentoufi AA; Havaux X; Kinet I; Cormont F; Bazin H; Latinne D
    Immunol Lett; 1999 Jun; 68(2-3):229-35. PubMed ID: 10424425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.